Digang, Merlina D.
HRN: 05-24-18 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/08/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
06/08/2022
06/14/2022
IV
4.5 G
Q6H
Methimazole-Induced Agranulocytosis; Febrile Neutropenia
Waiting Final Action
Indication: Empiric Type of Infection: Febrile Neutropenia Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes